Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Related Questions
Would you offer ultra-hypofractionated accelerated partial breast re-irradiation using 5 fractions?
Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?
What is your preferred method of surveillance after mastectomy?
Would you recommend PMRT in a patient with a triple negative cT2N0, ypT2N0 metaplastic breast cancer s/p NAC, mastectomy, and SLNB?
How would you approach radiation for an elderly patient with pT2N1 TNBC s/p MRM and ALND who refused chemo-immunotherapy?
Would you feel comfortable doing high tangents with ultra-hypofractionation?
Under what circumstances would you pursue completion ALND in a patient with multiple positive sentinel nodes after breast-conserving surgery?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?
What are your top takeaways in Breast Cancer from ESMO 2024?
Would you recommend PMRT for multifocal IDC with extensive LVI and 1 SLN with ITCs?
